Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €234.32 EUR
Change Today +3.12 / 1.35%
Volume 0.0
PY2 On Other Exchanges
As of 3:43 PM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

999 East Arques Avenue

Sunnyvale, CA 94085

United States

Phone: 408-774-0330

Fax: 408-774-0340

Pharmacyclics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of cancer and immune-mediated diseases. The company’s first commercial product is IMBRUVICA (ibrutinib), an oral, once-daily, single-agent therapy, which has demonstrated a survival advantage over an approved, standard-of-care therapy in a difficult-to-treat blood cancer. IMBRUVICA inhibits a protein called Bruton's tyrosine kinase (BTK), a key signaling molecule in the B-cell receptor signaling complex that plays a major role in the survival and spread of malignant B-cells (immune cells that can develop into antibody producing cells). IMBRUVICA blocks signals that tell malignant B-cells to multiply and spread uncontrollably. The company markets IMBRUVICA in the United States (U.S.) for its four the U.S. Food and Drug Administration approved indications for the treatment of patients with: chronic lymphocytic leukemia (CLL) who have received at least one prior therapy; all lines of CLL with deletion of the short arm of chromosome 17 (del 17p CLL); mantle cell lymphoma (MCL) who have received at least one prior therapy; and all lines of Waldenström's macroglobulinemia (WM). IMBRUVICA received the U.S. Food and Drug Administration approval via the new Breakthrough Therapy Designation pathway. IMBRUVICA is approved for use in approximately 40 countries, including the U.S., Canada, and the 28 countries which comprise the European Union. The company has other product candidates in clinical development and various pre-clinical molecules in lead optimization. Its pre-clinical molecules include BTK inhibitors for autoimmune disorders, such as rheumatoid arthritis. The company developed and commercialized IMBRUVICA in four indications, for the treatment of patients with: CLL who have received at least one prior therapy; all lines of del 17p CLL; MCL who have received one prior therapy; and all lines of WM. The company is pursuing multiple indications as part of its clinical development plan for IMBRUVICA, which include the following B-cell malignancies: CLL, small lymphocytic leukemia (SLL), MCL, follicular lymphoma, diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), WM, marginal zone lymphoma (MZL), acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and other cancer types. The company is also pursuing the development of IMBRUVICA for Graft versus host disease. In addition, the company has a pre-clinical testing program underway to develop novel inhibitors of BTK for inflammatory and autoimmune diseases. The company’s clinical development program examines product candidates that are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in life-threatening human diseases. IMBRUVICA, the company’s first product to market, is indicated for the treatment of specific subsets of CLL, MCL and WM patients. The company is continuing the development of IMBRUVICA across various B-cell malignancies, as well as in solid tumors and certain immune-mediated diseases. In addition to IMBRUVICA, the company has other product candidates in clinical development and several pre-clinical molecules in lead optimization; including a BTK inhibitor in a Phase I study in rheumatoid arthritis patients, an inhibitor of Factor VIIa (PCI-27483) and a HDAC inhibitor, abexinostat. Business Strategy The key elements of the company’s business strategy include extending IMBRUVICA’s reach and enhance its leadership position across hematology; establishing IMBRUVICA in multiple solid tumor indications; developing next-generation BTK inhibitors as a new standard-of-care for immune-mediated diseases; leveraging its core capabilities to ensure accelerated innovation and long-term growth; and focusing on profitability while investing to expand and sustain its business for the future. Customers The company sells IMBRUVICA directly to some customers who have in-house dispensing capabilities, specialty pharmacies that sell to individual patients, specialty distributors that sell to hospital pharmacies and other organizations that it has contracted with. Collaborations an


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PY2:GR €234.32 EUR +3.12

PY2 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Actelion Ltd SFr.133.00 CHF -1.40
Alexion Pharmaceuticals Inc $171.94 USD +3.37
BioMarin Pharmaceutical Inc $127.19 USD +0.31
Genmab A/S kr577.50 DKK +2.50
Vertex Pharmaceuticals Inc $125.08 USD +0.03
View Industry Companies

Industry Analysis


Industry Average

Valuation PY2 Industry Range
Price/Earnings 100.0x
Price/Sales 24.4x
Price/Book 22.5x
Price/Cash Flow 277.0x
TEV/Sales 23.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PHARMACYCLICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at